SOUTH SAN FRANCISCO — Longevity startup NewLimit raised $435 million in Series C funding and plans to launch its first clinical trial of a liver medicine. The South San Francisco-based company will use the proceeds to advance its research and development efforts in aging-related therapeutics.
Founders Fund led the financing round, with participation from Thrive Capital, Lilly Ventures, Nat Friedman, and Daniel Gross. The new funding brings NewLimit’s total capital raised to more than $610 million since its founding in 2021. The company announced a $130 million Series B round in May 2025 and raised an additional $45 million in October 2025.
According to co-founder and CEO Jacob Kimmel, NewLimit is now valued at approximately $3.1 billion. Kimmel, a stem cell biologist, co-founded the company in 2021 with Brian Armstrong, CEO and co-founder of Coinbase, and Blake Byers, a former GV partner and bioengineer.
The clinical trial will focus on a liver-targeted therapy developed through NewLimit’s platform for reprogramming cellular aging. The company has not disclosed the specific mechanism of action, patient population, or trial timeline. A spokesperson said the trial represents a key step in translating the company’s research on epigenetic reprogramming into potential treatments for age-related diseases.
NewLimit’s approach centers on restoring youthful gene expression patterns in aged cells. The company has published preclinical data suggesting its technology can reverse certain markers of biological aging in human cells. The liver medicine slated for clinical testing emerged from this research program.
In a podcast interview, Kimmel said the Series C funding will accelerate the company’s path toward human trials. He emphasized that the liver was selected as an initial target organ due to its central role in metabolism and regenerative capacity.